BUSINESS
Enhertu Scores in Earlier Line for HER2-Low Breast Cancer, Shows Promise in Ultralow Cases
Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) delivered favorable results in a global PIII trial targeting chemotherapy naïve patients with hormone receptor (HR) positive, HER2-low and -ultralow recurrent metastatic breast cancer. According to the latest data from the…
To read the full story
Related Article
- Enhertu Filed for HER2 Low or Ultralow Breast Cancer in Japan
October 7, 2024
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





